Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?

VRTX shares are down 7.9% over the past three months as Journavx and Casgevy sales came in below expectations, weighing on sentiment. Offsetting that weakness, CF growth remains solid, Alyftrek is gaining momentum, and renal pipeline progress provides support for the longer-term story.

Analysis

VRTX shares are down 7.9% over the past three months as Journavx and Casgevy sales came in below expectations, weighing on sentiment. Offsetting that weakness, CF growth remains solid, Alyftrek is gaining momentum, and renal pipeline progress provides support for the longer-term story.